It has been indicated that in B16 melanoma, CT26 colon cancer, or 4T1 breast cancer models, the injection of ADU-S100 effectively triggers CD8+ T cell responses in a STING-dependent manner and leads to significant tumor regression, exerting long-lasting antitumor effects (83). Here, CD8A is linked to breast cancer.